BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23027129)

  • 1. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
    Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
    Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
    Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
    Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
    Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
    Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
    Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
    Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
    Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
    Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
    Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.
    Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S
    Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
    Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
    Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.